Table 4.
Univariate and multivariate analyses for the primary endpoint
| Sustained VA Requiring ICD Therapy | ||||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | |||||
| Variables | HR | 95% CI | P Value | HR | 95% CI | P Value |
| Sex | 1.43 | 0.59–3.50 | 0.425 | — | — | — |
| NYHA class III/IV | 0.68 | 0.33–1.39 | 0.293 | — | — | — |
| Secondary prevention | 1.22 | 0.43–3.49 | 0.711 | — | — | — |
| AF | 0.65 | 0.16–2.70 | 0.553 | — | — | — |
| LBBB | 0.46 | 0.22–0.97 | 0.041 | 0.68 | 0.31–1.52 | 0.348 |
| MR grade 3–4 | 1.00 | 0.45–2.23 | 1.00 | — | — | — |
| LVEF‐CMR (10% step) | 1.04 | 0.65–1.67 | 0.862 | — | — | — |
| LVEDV‐CMR (10‐mL step) | 1.03 | 0.98–1.08 | 0.216 | — | — | — |
| RVEF‐CMR (10% step) | 0.90 | 0.71–1.13 | 0.365 | — | — | — |
| RVEDV‐CMR (10‐mL step) | 1.07 | 1.01–1.14 | 0.034 | 1.06 | 1.00–1.12 | 0.045 |
| LV aneurysm | 1.02 | 0.46–2.29 | 0.956 | — | — | — |
| LGE positivity | 5.79 | 0.80–42.14 | 0.084 | — | — | — |
| Ischemic LGE | 1.18 | 0.58–2.43 | 0.651 | — | — | — |
| Cx‐LGE | 3.27 | 1.59–6.74 | 0.001 | 3.22 | 1.56–6.65 | 0.002 |
Abbreviations: AF, atrial fibrillation; CI, confidence interval; CMR, cardiovascular magnetic resonance; Cx‐LGE, complex late gadolinium enhancement; HR, hazard ratio; ICD, implantable cardioverter‐defibrillator; LBBB, left bundle branch block; LGE, late gadolinium enhancement; LV, left ventricular; LVEDV‐CMR, left ventricular end‐diastolic volume measured with CMR; LVEF‐CMR, left ventricular ejection fraction measured with CMR; MR, mitral regurgitation; NYHA, New York Heart Association; RVEDV‐CMR, right ventricular end‐diastolic volume measured with CMR; RVEF‐CMR, right ventricular ejection fraction measured with CMR; VA, ventricular arrhythmia.